首页|黄芎抗栓方加味对卒中后抑郁患者血清炎性因子hs-CRP、IL-6水平的影响

黄芎抗栓方加味对卒中后抑郁患者血清炎性因子hs-CRP、IL-6水平的影响

扫码查看
目的:观察黄芎抗栓方加味对卒中后抑郁(PSD)患者血清炎性因子超敏-C反应蛋白(hs-CRP)、白介素-6(IL-6)水平的影响.方法:62例于2022年12月1日—2023年12月1日在安徽中医药大学第一附属医院(安徽省中医院)老年病中心脑病科住院的PSD患者被随机分为对照组和观察组,每组31例.两组均采用常规治疗,对照组口服草酸艾司西酞普兰片,10 mg/次,1次/d;观察组在对照组治疗基础上口服黄芎抗栓方加味中药汤剂.两组均治疗4周.4周后观察两组患者血清hs-CRP、IL-6水平的变化,以及美国国立卫生研究院卒中量表(NIHSS)、汉密尔顿抑郁量表(HAMD)、汉良Barthel指数(MBI)量表、匹兹堡睡眠质量指数(PSQI)量表评分的变化.结果:治疗后两组患者血清hs-CRP、IL-6水平以及NIHSS、HAMD、PSQI评分均较治疗前下降,MBI评分较治疗前升高,差异有统计学意义(P<0.01).治疗后观察组患者血清hs-CRP、IL-6水平以及NIHSS、HAMD、PSQI评分低于对照组,MBI评分及总有效率高于对照组,差异有统计学意义(P<0.05,P<0.01);两组不良反应率比较,差异无统计学意义(P>0.05).结论:黄芎抗栓方加味能够降低PSD患者血清炎性因子水平,减轻抑郁症状,提高日常生活能力,降低不良情绪发生的频率,不良反应较小,疗效良好,可供临床使用.
Effect of Modified Huangxiong Antithrombotic Formula on serum inflammatory factors hs-CRP and IL-6 levels in patients with post-stroke depression
Objective:To observe the effect of Modified Huangxiong Antithrombotic Formula on serum inflammatory factors high-sensitivity C-reactive protein(hs-CRP)and interleukin-6(IL-6)levels in patients with post-stroke depression(PSD).Methods:Sixty-two PSD patients admitted to the Department of Encephalopathy of the Geriatric Center at the First Affiliated Hospital of Anhui University of Chinese Medicine(Anhui Provincial Hospital of Traditional Chinese Medicine)between December 1,2022,and December 1,2023,were randomly divided into a control group and an observation group,with 31 patients in each group.Patients in both groups received conventional treatment.Patients in the control group took es-citalopram oxalate tablets orally,10 mg/time,1 time/day.Patients in the observation group took Modified Huangqiong Anti-thrombotic Formula in addition to the treatment given to the control group.Patients in both groups were treated for four weeks.After four weeks,changes in serum hs-CRP and IL-6 levels,as well as NIH Stroke Scale(NIHSS),Hamilton De-pression Rating Scale(HAMD),Modified Barthel Index(MBI),and Pittsburgh Sleep Quality Index(PSQI)scores were ob-served.Results:After treatment,serum hs-CRP and IL-6 levels,as well as NIHSS,HAMD,and PSQI scores decreased,while MBI scores increased in both groups,with statistically significant differences(P<0.01).After treatment,serum hs-CRP and IL-6 levels,as well as NIHSS,HAMD,and PSQI scores were lower in the observation group compared to those of the control group,while MBI scores and overall effective rates were higher,with statistically significant differences(P<0.05,P<0.01).There was no statistically significant difference in adverse reaction rates between the two groups(P>0.05).Conclusion:The Modified Huangxiong Antithrombotic Formula can reduce serum inflammatory factor levels in patients with PSD,alleviate depressive symptoms,improve daily living abilities,and reduce the frequency of bad moods.It has minimal adverse reactions and good therapeutic effects,making it suitable for clinical use.

PSDhs-CRPModified Huangxiong Antithrombotic Formulainterleukin-6escitalopram oxalate

苏镇红、曹仕健、司佳佳、耿伟富

展开 >

安徽中医药大学第一附属医院,安徽 合肥 230031

卒中后抑郁 超敏C反应蛋白 黄芎抗栓方加味 白介素-6 草酸艾司西肽普兰

2024

山西中医药大学学报

山西中医药大学学报

ISSN:
年,卷(期):2024.25(11)